Zai Lab Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $25.49
- Today's High:
- $26.55
- Open Price:
- $25.49
- 52W Low:
- $20.975
- 52W High:
- $51.489
- Prev. Close:
- $26.47
- Volume:
- 208825
Company Statistics
- Market Cap.:
- $2.71 billion
- Book Value:
- 9.626
- Revenue TTM:
- $251.80 million
- Operating Margin TTM:
- -156.83%
- Gross Profit TTM:
- $-145386000
- Profit Margin:
- -156.08%
- Return on Assets TTM:
- -19.55%
- Return on Equity TTM:
- -36.65%
Company Profile
Zai Lab Ltd had its IPO on 2017-09-20 under the ticker symbol ZLAB.
The company operates in the Healthcare sector and Biotechnology industry. Zai Lab Ltd has a staff strength of 2,036 employees.
Stock update
Shares of Zai Lab Ltd opened at $25.49 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $25.49 - $26.55, and closed at $26.54.
This is a +0.26% increase from the previous day's closing price.
A total volume of 208,825 shares were traded at the close of the day’s session.
In the last one week, shares of Zai Lab Ltd have increased by +1.69%.
Zai Lab Ltd's Key Ratios
Zai Lab Ltd has a market cap of $2.71 billion, indicating a price to book ratio of 3.1058 and a price to sales ratio of 17.1288.
In the last 12-months Zai Lab Ltd’s revenue was $251.80 million with a gross profit of $-145386000 and an EBITDA of $-385892992. The EBITDA ratio measures Zai Lab Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Zai Lab Ltd’s operating margin was -156.83% while its return on assets stood at -19.55% with a return of equity of -36.65%.
In Q2, Zai Lab Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 42.9%.
Zai Lab Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.84 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Zai Lab Ltd’s profitability.
Zai Lab Ltd stock is trading at a EV to sales ratio of 12.5309 and a EV to EBITDA ratio of -4.723. Its price to sales ratio in the trailing 12-months stood at 17.1288.
Zai Lab Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.11 billion
- Total Liabilities
- $133.35 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $2.35 million
- Dividend Payout Ratio
- 0%
Zai Lab Ltd ended 2023 with $1.11 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.11 billion while shareholder equity stood at $932.31 million.
Zai Lab Ltd ended 2023 with $0 in deferred long-term liabilities, $133.35 million in other current liabilities, 6000.00 in common stock, $-2031399000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $859.16 million and cash and short-term investments were $874.66 million. The company’s total short-term debt was $7,299,000 while long-term debt stood at $0.
Zai Lab Ltd’s total current assets stands at $1.02 billion while long-term investments were $5.13 million and short-term investments were $15.50 million. Its net receivables were $68.06 million compared to accounts payable of $67.03 million and inventory worth $36.35 million.
In 2023, Zai Lab Ltd's operating cash flow was $0 while its capital expenditure stood at $2.35 million.
Comparatively, Zai Lab Ltd paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $26.54
- 52-Week High
- $51.489
- 52-Week Low
- $20.975
- Analyst Target Price
- $73.18
Zai Lab Ltd stock is currently trading at $26.54 per share. It touched a 52-week high of $51.489 and a 52-week low of $51.489. Analysts tracking the stock have a 12-month average target price of $73.18.
Its 50-day moving average was $27.06 and 200-day moving average was $33.08 The short ratio stood at 7.24 indicating a short percent outstanding of 0%.
Around 182.5% of the company’s stock are held by insiders while 5855.1% are held by institutions.
Frequently Asked Questions About Zai Lab Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.